PL1711531T3 - Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania - Google Patents

Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania

Info

Publication number
PL1711531T3
PL1711531T3 PL04817634T PL04817634T PL1711531T3 PL 1711531 T3 PL1711531 T3 PL 1711531T3 PL 04817634 T PL04817634 T PL 04817634T PL 04817634 T PL04817634 T PL 04817634T PL 1711531 T3 PL1711531 T3 PL 1711531T3
Authority
PL
Poland
Prior art keywords
methods
antibodies
tlr4
neutralizing anti
monoclonal antibodies
Prior art date
Application number
PL04817634T
Other languages
English (en)
Inventor
Greg Christopher Andrew Elson
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of PL1711531T3 publication Critical patent/PL1711531T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL04817634T 2003-12-10 2004-12-10 Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania PL1711531T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52896203P 2003-12-10 2003-12-10
US52881203P 2003-12-10 2003-12-10
US52881103P 2003-12-10 2003-12-10
PCT/IB2004/004433 WO2005065015A2 (en) 2003-12-10 2004-12-10 Neutralizing antibodies and methods of use thereof
EP04817634A EP1711531B9 (en) 2003-12-10 2004-12-10 Neutralizing anti tlr4/md-2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PL1711531T3 true PL1711531T3 (pl) 2012-07-31

Family

ID=34753681

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04817634T PL1711531T3 (pl) 2003-12-10 2004-12-10 Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania

Country Status (10)

Country Link
EP (1) EP1711531B9 (pl)
JP (1) JP4762152B2 (pl)
AT (1) ATE544783T1 (pl)
AU (1) AU2004311541B2 (pl)
CA (1) CA2548990C (pl)
DK (1) DK1711531T3 (pl)
ES (1) ES2382039T3 (pl)
PL (1) PL1711531T3 (pl)
PT (1) PT1711531E (pl)
WO (1) WO2005065015A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
WO2006077471A2 (en) * 2004-12-10 2006-07-27 Novimmune S.A. Combining therapies targeting multiple toll-like receptors and use thereof
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
MX2009012319A (es) 2007-05-14 2010-03-01 Novimmune Sa Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
AU2012205763B2 (en) 2011-01-10 2016-12-22 Novimmune S.A. Anti-TLR4 antibodies and methods of use thereof
CN104540851B (zh) 2012-03-29 2017-09-15 诺夫免疫股份有限公司 抗tlr4抗体及其用途
EP3060250A1 (en) 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
JP2017501995A (ja) 2013-12-06 2017-01-19 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用方法
WO2015129858A1 (ja) 2014-02-28 2015-09-03 アステラス製薬株式会社 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
KR101745520B1 (ko) * 2015-05-29 2017-06-12 아주대학교산학협력단 신규한 tlr4 길항제
WO2018085617A1 (en) * 2016-11-07 2018-05-11 Argos Therapeutics, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
GB202408008D0 (en) * 2024-06-05 2024-07-17 Cambridge Entpr Ltd TLR4 antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity

Also Published As

Publication number Publication date
AU2004311541A1 (en) 2005-07-21
PT1711531E (pt) 2012-04-18
ES2382039T3 (es) 2012-06-04
AU2004311541B2 (en) 2011-06-30
JP4762152B2 (ja) 2011-08-31
DK1711531T3 (da) 2012-04-30
WO2005065015A3 (en) 2005-12-01
CA2548990C (en) 2014-09-23
ATE544783T1 (de) 2012-02-15
CA2548990A1 (en) 2005-07-21
EP1711531B1 (en) 2012-02-08
WO2005065015A2 (en) 2005-07-21
JP2007517503A (ja) 2007-07-05
EP1711531A2 (en) 2006-10-18
EP1711531B9 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
PL1711531T3 (pl) Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
UA104132C2 (en) Humanized antibodies against tl1a
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2005121179A3 (en) Transferrin receptor antibodies
LUC00025I1 (pl)
WO2008063776A3 (en) Antibodies to lymphotoxin-alpha
NZ600262A (en) Anti-her3 antibodies and uses thereof
WO2009036209A3 (en) Homogeneous antibody populations
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
TW200700081A (en) Anti-ctla-4 antibody compositions
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
TW200716182A (en) Antibodies directed to CD20 and uses thereof
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody